Jennison Associates LLC trimmed its holdings in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 88.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 33,594 shares of the company's stock after selling 269,927 shares during the quarter. Jennison Associates LLC owned 0.12% of Krystal Biotech worth $6,057,000 at the end of the most recent quarter.
Other institutional investors and hedge funds also recently modified their holdings of the company. Teacher Retirement System of Texas increased its position in shares of Krystal Biotech by 27.3% during the fourth quarter. Teacher Retirement System of Texas now owns 6,383 shares of the company's stock valued at $1,000,000 after acquiring an additional 1,369 shares during the last quarter. Fifth Third Bancorp increased its position in Krystal Biotech by 159.1% in the first quarter. Fifth Third Bancorp now owns 171 shares of the company's stock worth $31,000 after buying an additional 105 shares during the last quarter. JPMorgan Chase & Co. increased its position in Krystal Biotech by 18.7% in the fourth quarter. JPMorgan Chase & Co. now owns 151,835 shares of the company's stock worth $23,786,000 after buying an additional 23,934 shares during the last quarter. Federated Hermes Inc. increased its position in Krystal Biotech by 1.8% in the fourth quarter. Federated Hermes Inc. now owns 13,048 shares of the company's stock worth $2,044,000 after buying an additional 229 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in Krystal Biotech by 179.3% in the first quarter. GAMMA Investing LLC now owns 673 shares of the company's stock worth $121,000 after buying an additional 432 shares during the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In other Krystal Biotech news, insider Suma Krishnan sold 1,389 shares of the firm's stock in a transaction dated Wednesday, July 16th. The stock was sold at an average price of $150.00, for a total transaction of $208,350.00. Following the sale, the insider owned 1,508,056 shares in the company, valued at $226,208,400. This trade represents a 0.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 49,800 shares of company stock worth $7,487,943 in the last quarter. Company insiders own 13.70% of the company's stock.
Krystal Biotech Price Performance
Krystal Biotech stock opened at $147.49 on Monday. Krystal Biotech, Inc. has a one year low of $122.80 and a one year high of $219.34. The business has a fifty day moving average price of $136.57 and a 200-day moving average price of $155.93. The firm has a market capitalization of $4.26 billion, a P/E ratio of 35.45 and a beta of 0.67.
Krystal Biotech (NASDAQ:KRYS - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 37.17% and a return on equity of 14.64%. The business had revenue of $88.18 million for the quarter, compared to the consensus estimate of $98.66 million. Sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts have issued reports on the company. Chardan Capital reissued a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a research report on Wednesday, May 7th. Citigroup reissued a "neutral" rating and issued a $176.00 target price (up from $155.00) on shares of Krystal Biotech in a research report on Wednesday, July 9th. HC Wainwright reissued a "buy" rating and issued a $240.00 target price on shares of Krystal Biotech in a research report on Tuesday, June 24th. Finally, Guggenheim decreased their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $213.75.
Check Out Our Latest Analysis on KRYS
Krystal Biotech Company Profile
(
Free Report)
Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Krystal Biotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Krystal Biotech wasn't on the list.
While Krystal Biotech currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
